0001472375-18-000137.txt : 20181113 0001472375-18-000137.hdr.sgml : 20181113 20181113140315 ACCESSION NUMBER: 0001472375-18-000137 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001357878 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 980479983 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53230 FILM NUMBER: 181177107 BUSINESS ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: (702) 805-7525 MAIL ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: Eternelle Skincare Products Inc. DATE OF NAME CHANGE: 20170621 FORMER COMPANY: FORMER CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20111007 FORMER COMPANY: FORMER CONFORMED NAME: CREENERGY Corp DATE OF NAME CHANGE: 20100818 10-Q 1 form10q.htm QUARTERLY REPORT FOR THE QUARTERLY ENDED SEPTEMBER 30, 2018 Filed by Avantafile.com - Peptide Technologies, Inc. - Form 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

 

Commission File No. 000-53230

PEPTIDE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter) 

 

Nevada

 

98-0479983

(State or other jurisdiction of

 

(IRS Employer

incorporation or organization)

 

Identification No.)

 

5348 Vegas Drive #177

Las Vegas, NV 89108

(Address of principal executive offices)

 

(702) 948-8893

Registrant’s telephone number, including area code

 

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:

Yes [  ] No [X]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

[  ]

Accelerated filer

[   ]

Non–Accelerated filer

[  ]

Smaller reporting company

[X]

 

 

Emerging growth company

[   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).

Yes [  ] No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

  

Class

 

Outstanding at November 5, 2018

Common stock, $0.001 par value

 

127,112,660


 PEPTIDE TECHNOLOGIES, INC.

INDEX TO FORM 10-Q FILING

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

TABLE OF CONTENTS

 

  PAGE
PART I - FINANCIAL INFORMATION  
   
Item 1. Financial Statements (Unaudited) 1
  Balance Sheets 2
  Statements of Operations 3
  Statements of Cash Flows 4
  Notes to Financial Statements 5
Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 7
Item 3 Quantitative and Qualitative Disclosures About Market Risk 9
Item 4. Controls and Procedures 9
     
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings 11
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 11
Item 3. Defaults Upon Senior Securities 11
Item 4. Mining Safety Disclosures 11
Item 5 Other Information 11
Item 6. Exhibits 11
     
CERTIFICATIONS  
   
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act  
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act  
32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act  
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act  

  PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included, and all such adjustments are of a normal recurring nature. Operating results for the three and six months ended September 30, 2018 are not necessarily indicative of the results that can be expected for the year ending March 31, 2019.

1


PEPTIDE TECHNOLOGIES, INC.

BALANCE SHEETS

(UNAUDITED)

 

  September 30, 2018     March 31, 2018  
ASSETS            
             
Current Assets            
Cash and cash equivalents $ 1,083   $ 1,728  
Total Current Assets   1,083     1,728  
             
Website   10,667     13,341  
             
Total Assets $ 11,750   $ 15,069  
             
LIABILITIES AND STOCKHOLDERS’ DEFICIT            
             
Current Liabilities            
Accounts payable $ 53,454   $ 37,870  
Related party advances   67,592     67,113  
Accrued compensation   221,192     221,192  
Other accrued liabilities   14,000     10,000  
Total Current Liabilities   356,238     336,175  
             
Stockholders’ Deficit            
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of September 30, 2018 and March 31, 2018   127,113     127,113  
Additional paid-in capital   731,963     731,963  
Accumulated deficit   (1,203,564 )   (1,180,182 )
Total Stockholders’ Deficit   (344,488 )   (321,106 )
Total Liabilities and Stockholders’ Deficit $ 11,750   $ 15,069  

  

The accompanying notes are an integral part of these unaudited financial statements.

2


PEPTIDE TECHNOLOGIES, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED) 

 

  Three Months Ended     Six Months Ended
  September 30,     September 30,
  2018   2017     2018 2017  
Operating Expenses                        
General and administrative $ 4,820   $ 8,144   $ 23,389   $ 25,247  
Total Operating Expenses   4,820     8,144     23,389     25,247  
                         
Operating Loss   (4,820 )   (8,144 )   (23,389 )   (25,247 )
                         
Other Expense                        
 Foreign currency gain   11     17     7     17  
Net Loss $ (4,809 ) $ (8,127 ) $ (23,382 ) $ (25,230 )
                         
Basic and Diluted Loss per Common Share $   $   $   $  
Weighted Average Number of Common Shares Outstanding   127,112,660     156,062,660     127,112,660     156,062,660  

 

 The accompanying notes are an integral part of these unaudited financial statements.

3


 PEPTIDE TECHNOLOGIES, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED) 

 

        For the Six Months Ended  
        September 30,  
    2018     2017  
Cash Flows From Operating Activities:            
Net loss $ (23,382 ) $ (25,230 )
Adjustments to reconcile net loss to cash used in operating activities            
Depreciation and amortization   2,674      
Changes in operating assets and liabilities:            
Accounts payable and accrued liabilities   19,584     5,000  
Net cash used in operating activities   (1,124 )   (20,230 )
             
Cash Flows From Investing Activities:            
Website development       (16,000 )
Net cash used in investing activities       (16,000 )
             
Cash Flows From Financing Activities:            
Related party advances   479     39,536  
Net cash provided by financing activities   479     39,536  
             
(Decrease) increase in cash and equivalents   (645 )   3,306  
Cash and cash equivalents, beginning of period   1,728      
Cash and cash equivalents, end of period $ 1,083   $ 3,306  

  

The accompanying notes are an integral part of these unaudited financial statements.

4


PEPTIDE TECHNOLOGIES, INC.

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018 AND 2017

(Unaudited)

 

 

NOTE 1 – NATURE OF OPERATIONS

Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties.

The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly.

The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies.

The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

 

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the three and six months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2018 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2018 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

5


NOTE 3 – GOING CONCERN

 

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,203,564 as of September 30, 2018. The Company also has excess liabilities over assets of $344,488. These factors raise doubt about the Company’s ability to continue as a going concern.

 

Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

 

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. 

 

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.

 

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.

 

Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

 

NOTE 5 – RELATED PARTY TRANSACTIONS 

The Company’s Chief Financial Officer (“CFO”) advanced $479 and $39,536 to the Company during the six months ended September 30, 2018 and 2017, respectively, to pay for operating expenses and website development costs. The advances are due on demand and carry no interest. The related party advances totaled $67,592 and $67,113 as of September 30, 2018 and March 31, 2018, respectively.

6


NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

 

NOTE 7 – SUBSEQUENT EVENTS

In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest.  The advances are non-interest bearing.

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

In this Quarterly Report, “Company,” “our company,” “us,” and “our” refer to Peptide Technologies, Inc., unless the context requires otherwise.

 

Forward-Looking Statements

 

The following information contains certain forward-looking statements. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “could,” “expect,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

 

Business of Issuer

 

The business of Peptide Technologies, Inc. (the “Company” or “Peptide”) is to develop and market skincare products. The Company does business as Eternelle Skincare Products. Peptides are the latest innovation in skincare as science has proven that peptides can help manage wrinkles in skin and reverse the signs of aging. Using proprietary peptide blends, the Company has a number of skincare products that demonstrate strong efficacy in providing youthful, healthy skin and significant anti-aging benefits to both women and men.

 

Our skincare products address various skincare needs. These products include moisturizers and serums for the face and around the eyes.

  1. Skin Brightener – A unique pigment clarifying serum that addresses uneven production of melanin. It synergistically targets areas of hyper pigmentation.
  2. Vitamin C Peptide – Plant-based collagen serum created to resist damage from aging, sun damage, and environmental exposure.
  3. Skin Moisturizer – A super fruit, antioxidant rich crème that contains age defying peptides and vitamin C that significantly minimizes visible signs of aging.

Our Company has developed its proprietary skincare formulations, and we will use internationally recognized experts in the manufacturing of specialized, professional quality products that meet the demands of day and resort spa, medical spa, and eco spa markets.

The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. With profound knowledge and expertise in cosmetic chemistry and professional skincare, this manufacturer has established itself as a leader in cutting edge formulations and product innovation in the field of skincare.

7


This manufacturer offers custom product formulation and manufacturing, allowing our Company to develop proprietary blends in order to privately brand our collection.

This supplier manufactures products in accordance with Good Manufacturing Procedures (GMP). It also follows the recommendations of the United States Food and Drug Administration and Health Canada and also adheres to the Quality Assurance Guidelines of the Cosmetic, Toiletry, and Fragrance Association. These guidelines enable us to guarantee the consistency and quality of our products from batch to batch. The manufacturer performs toxicity, microbiological, temperature, and stability tests on all formulations. They do not test on animals, and they select all botanicals for freshness, purity of source, quality, and potency. Every product will be researched and tested by the supplier’s manufacturing team before it is approved for sale.

We expect to launch our products and begin recognizing revenue by the fourth quarter of this fiscal year. 

 

Financial Results and Trends

 

Results of Operations for the Six Months Ended September 30, 2018 and 2017

 

At present, the Company has no revenue. Net loss decreased from $25,230 for the six months ended September 30, 2017 to $23,382 for the six months ended September 30, 2018 due to lower general and administrative expenses.

 

Liquidity and Capital Resources

 

The Company requires significant cash to launch its business and reduce its payables. The Company’s primary sources of liquidity and capital resources have been related party advances, which are not sufficient prospectively.  These factors raise substantial doubt about the Company’s ability to continue as a going concern. We are actively seeking to raise additional debt and/or equity capital to add new products and/or services to commence material operations. If the Company is unable to raise additional capital in the near future or meet financing requirements, the Company may need to curtail or alter its plan of operation.

 

Cash Flow

 

The following table summarizes, for the periods indicated, selected items in our condensed Statements of Cash Flows:

 

  Six Months Ended  
  September 30,  
  2018   2017  
Net cash (used in) provided by:            
Operating activities $ (1,124 ) $ (20,230 )
Investing activities $   $ (16,000 )
Financing activities $ 479   $ 39,536  

 

Operating Activities

 

Cash used in operating activities was $1,124 and $20,230 for the six months ended September 30, 2018 and 2017, respectively. The decrease in cash used in operating activities was primarily due to changes in working capital.

 

Investing Activities

 

Cash used in investing activities was $0 and $16,000 for the six months ended September 30, 2018 and 2017, respectively. The decrease in cash used in investing activities was primarily due to non-recurring website development costs in 2017.

8


Financing Activities

 

Cash provided by financing activities was $479 and $39,536 for the six months ended September 30, 2018 and 2017, respectively. The decrease in cash provided by financing activities was primarily due to lower related party advances.

 

Off-Balance Sheet Arrangements

 

None.

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Registration Statement on Form 10-12G, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We had no material changes in market risk from those described in “Item 2—Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K.

 

ITEM 4. CONTROLS AND PROCEDURES 

This report includes the certification of our Chief Executive Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations revered to in those certifications.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives.

 

As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer need to carry out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer concluded that our disclosure controls and procedures were effective as of September 30, 2018.

                                                                                 

Management’s Report on Internal Control over Financial Reporting

 

Our Chief Executive Officer and the Chief Financial Officer are responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of our internal control over financial reporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. GAAP. Internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (c) provide reasonable assurance that receipts and expenditures are being made only in accordance with appropriate authorization of management and the Board of Directors, and (d) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

9


In connection with the preparation of our Annual Report on Form 10-K for the year ended March 31, 2019, our Chief Executive Officer and Chief Financial Officer will evaluate the effectiveness of our internal control over financial reporting as of March 31, 2019.

 

Inherent Limitations on Internal Controls

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Limitations inherent in any control system include the following:

 

 

Judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes;

 

 

 

 

Controls can be circumvented by individuals, acting alone or in collusion with others, or by management override;

 

 

 

 

The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;

 

 

 

 

Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures; and

 

 

 

 

The design of a control system must reflect the fact that resources are constrained, and the benefits of controls must be considered relative to their costs.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

10


PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

As of September 30, 2018, the Company is not involved in any material litigation.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

 

During the three months ended September 30, 2018, Peptide did not sell any unregistered equity securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

There is no information with respect to which information is not otherwise called for by this form.

  

ITEM 6. EXHIBITS

 

Exhibits

 

3.0

Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

 

 

3.1

Amended Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

 

 

3.2

Amended Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

 

 

3.3

Corporate Bylaws.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

 

 

10.1

Advance from Baxter Koehn to Peptide Technologies, Inc.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

 

 

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

 

 

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

 

 

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

 

 

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

11


SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant

Peptide Technologies, Inc.

 

 

Date: November 13, 2018

By:

/s/ Bruce Sellars

 

Bruce Sellars

 

Chief Executive Officer


EX-31.1 2 exhibit31-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 31.1

Exhibit 31.1

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending September 30, 2018

 

I, Bruce Sellars, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Peptide Technologies, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c.

Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

 

 

 

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant

Peptide Technologies, Inc.

 

 

Date: November 13, 2018

By:

/s/ Bruce Sellars

 

Bruce Sellars

 

Chief Executive Officer (Principal Executive Officer)



EX-31.2 3 exhibit31-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 31.2

Exhibit 31.2

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending September 30, 2018

 

I, Baxter Koehn, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Peptide Technologies, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant

Peptide Technologies, Inc.

 

 

Date: November 13, 2018

By:

/s/ Baxter Koehn

 

Baxter Koehn

 

Chief Financial Officer (Principal Financial Officer)



EX-32.1 4 exhibit32-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 32.1

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Peptide Technologies, Inc. (the ‘Company’) on Form 10-Q for the period ending September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Bruce Sellars, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant

Peptide Technologies, Inc.

 

 

Date: November 13, 2018

By:

/s/ Bruce Sellars

 

Bruce Sellars

 

Chief Executive Officer (Principal Executive Officer)



EX-32.2 5 exhibit32-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 32.2

Exhibit 32.2

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Peptide Technologies, Inc. (the ‘Company’) on Form 10-Q for the period ending September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Baxter Koehn, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant

Peptide Technologies, Inc.

 

 

Date: November 13, 2018

By:

/s/ Baxter Koehn

 

Baxter Koehn

 

Chief Financial Officer (Principal Financial Officer)



GRAPHIC 6 logo.gif begin 644 logo.gif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
EX-101.INS 7 pept-20180930.xml INSTANCE DOCUMENT 0001357878 2018-04-01 2018-09-30 0001357878 2018-11-12 0001357878 2018-09-30 0001357878 2018-03-31 0001357878 2017-04-01 2017-09-30 0001357878 2017-09-30 0001357878 us-gaap:ChiefFinancialOfficerMember 2018-09-30 0001357878 us-gaap:ChiefFinancialOfficerMember 2017-09-30 0001357878 2017-03-31 0001357878 2018-07-01 2018-09-30 0001357878 2017-07-01 2017-09-30 0001357878 2018-10-01 2018-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PEPTIDE TECHNOLOGIES, INC. 0001357878 10-Q 2018-09-30 false --03-31 Yes Non-accelerated Filer 2018 127112660 1083 1728 3306 67592 67113 479 39536 2005-11-18 P3Y 2674 1344 Q2 0.001 0.001 675000000 675000000 127112660 127112660 127112660 127112660 true false 10667 13341 1083 1728 11750 15069 356238 336175 14000 10000 221192 221192 53454 37870 11750 15069 -344488 -321106 -1203564 -1180182 731963 731963 127113 127113 127112660 156062660 127112660 156062660 -23382 -25230 -4809 -8127 7 17 11 17 -23389 -25247 -4820 -8144 23389 25247 4820 8144 23389 25247 4820 8144 -645 3306 479 39536 479 39536 -16000 16000 1124 20230 19584 5000 2674 23382 25230 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8211; NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">Peptide Technologies, Inc. (the &#8220;Company&#8221; or &#8220;Peptide&#8221;), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The Company&#8217;s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company&#8217;s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company&#8217;s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand&#8217;s value quickly.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8211; GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,203,564 as of September 30, 2018. The Company also has excess liabilities over assets of $344,488. These factors raise doubt about the Company&#8217;s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management&#8217;s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211;SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Revenue Recognition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer&#8217;s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Website</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expenditures related to the planning and operation of the Company&#8217;s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website&#8217;s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Financial Accounting Standards Board issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the Accounting Standards Codification (&#8220;ASC&#8221;). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><b>NOTE 5 &#8211; RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) advanced $479 and $39,536 to the Company during the six months ended September 30, 2018 and 2017, respectively, to pay for operating expenses and website development costs. The advances are due on demand and carry no interest. The related party advances totaled $67,592 and $67,113 as of September 30, 2018 and March 31, 2018, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><b>NOTE 6 &#8211; COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><b>NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide&#8217;s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Revenue Recognition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer&#8217;s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Website</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expenditures related to the planning and operation of the Company&#8217;s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website&#8217;s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Financial Accounting Standards Board issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the Accounting Standards Codification (&#8220;ASC&#8221;). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.</p> In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing. EX-101.SCH 8 pept-20180930.xsd SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature Of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis Of Presentation Of Interim Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Nature Of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 pept-20180930_cal.xml CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 pept-20180930_def.xml DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 pept-20180930_lab.xml LABELS LINKBASE DOCUMENT Related Party [Axis] Chief Financial Officer [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Small Business Is Entity Emerging Growth Company? Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Total Current Assets Website Total Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Accounts payable Related-party advances Accrued compensation Other accrued liabilities Total Current Liabilities Commitments and Contingencies Stockholders' Deficit Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of September 30, 2018 and March 31, 2018 Additional paid-in capital Accumulated deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Common stock par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses General and administrative Total Operating Expenses Operating Loss Other Expense Foreign currency loss Net Loss Basic and Diluted Loss per Common Share Weighted Average Number of Common Shares Outstanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net loss Adjustments to reconcile net loss to cash flows used in operating activities Depreciation and amortization Changes in operating assets and liabilities: Accounts payable and accrued liabilities Net cash used for operating activities Cash Flows From Investing Activities: Website development Net cash used for investing activities Cash Flows From Financing Activities: Related-party advances Net cash provided by financing activities (Decrease) increase in cash and equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature Of Operations Accounting Policies [Abstract] Basis Of Presentation Of Interim Financial Statements Going Concern Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Subsequent Events [Abstract] Subsequent Events Revenue Recognition Website Recent Accounting Pronouncements Date of Incorporation Accumulated deficit Total Stockholders' Deficit Website Estimated Useful Life Amortization Expense, Website Statement [Table] Statement [Line Items] Related party advances Date of Event Description Operating Expenses [Default Label] Operating Income (Loss) Net Income (Loss) Attributable to Parent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Cash Provided by (Used in) Operating Activities Payments for Software Net Cash Provided by (Used in) Investing Activities Increase (Decrease) in Notes Payable, Related Parties Net Cash Provided by (Used in) Financing Activities Property, Plant and Equipment, Preproduction Design and Development Costs [Policy Text Block] EX-101.PRE 12 pept-20180930_pre.xml PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Sep. 30, 2018
Nov. 12, 2018
Document And Entity Information    
Entity Registrant Name PEPTIDE TECHNOLOGIES, INC.  
Entity Central Index Key 0001357878  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   127,112,660
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2018  
Entity Small Business true  
Is Entity Emerging Growth Company? false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Current Assets    
Cash and cash equivalents $ 1,083 $ 1,728
Total Current Assets 1,083 1,728
Website 10,667 13,341
Total Assets 11,750 15,069
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Accounts payable 53,454 37,870
Related-party advances 67,592 67,113
Accrued compensation 221,192 221,192
Other accrued liabilities 14,000 10,000
Total Current Liabilities 356,238 336,175
Stockholders' Deficit    
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of September 30, 2018 and March 31, 2018 127,113 127,113
Additional paid-in capital 731,963 731,963
Accumulated deficit (1,203,564) (1,180,182)
Total Stockholders' Deficit (344,488) (321,106)
Total Liabilities and Stockholders' Deficit $ 11,750 $ 15,069
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Mar. 31, 2018
Statement of Financial Position [Abstract]    
Common stock par value $ 0.001 $ 0.001
Common stock, shares authorized 675,000,000 675,000,000
Common stock, shares issued 127,112,660 127,112,660
Common stock, shares outstanding 127,112,660 127,112,660
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Operating Expenses        
General and administrative $ 4,820 $ 8,144 $ 23,389 $ 25,247
Total Operating Expenses 4,820 8,144 23,389 25,247
Operating Loss (4,820) (8,144) (23,389) (25,247)
Other Expense        
Foreign currency loss 11 17 7 17
Net Loss $ (4,809) $ (8,127) $ (23,382) $ (25,230)
Basic and Diluted Loss per Common Share
Weighted Average Number of Common Shares Outstanding 127,112,660 156,062,660 127,112,660 156,062,660
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Statements of Cash Flows - USD ($)
6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows From Operating Activities:    
Net loss $ (23,382) $ (25,230)
Adjustments to reconcile net loss to cash flows used in operating activities    
Depreciation and amortization 2,674
Changes in operating assets and liabilities:    
Accounts payable and accrued liabilities 19,584 5,000
Net cash used for operating activities (1,124) (20,230)
Cash Flows From Investing Activities:    
Website development (16,000)
Net cash used for investing activities (16,000)
Cash Flows From Financing Activities:    
Related-party advances 479 39,536
Net cash provided by financing activities 479 39,536
(Decrease) increase in cash and equivalents (645) 3,306
Cash and cash equivalents, beginning of period 1,728
Cash and cash equivalents, end of period $ 1,083 $ 3,306
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature Of Operations
6 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature Of Operations

NOTE 1 – NATURE OF OPERATIONS

 

Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties.

The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly.

The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies.

The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern
6 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 3 – GOING CONCERN

 

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,203,564 as of September 30, 2018. The Company also has excess liabilities over assets of $344,488. These factors raise doubt about the Company’s ability to continue as a going concern.

 

Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

 

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. 

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies
6 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.

 

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.

 

Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
6 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 5 – RELATED PARTY TRANSACTIONS

 

The Company’s Chief Financial Officer (“CFO”) advanced $479 and $39,536 to the Company during the six months ended September 30, 2018 and 2017, respectively, to pay for operating expenses and website development costs. The advances are due on demand and carry no interest. The related party advances totaled $67,592 and $67,113 as of September 30, 2018 and March 31, 2018, respectively.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies
6 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments And Contingencies

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
6 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

NOTE 7 – SUBSEQUENT EVENTS

 

In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
6 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Revenue Recognition

Revenue Recognition

 

Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue by the fourth quarter of this fiscal year.

Website

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and depreciated over the website’s estimated useful life of three (3) years. Amortization expense for the three and six months ended September 30, 2018 was $1,344 and $2,674, respectively. There was no amortization expense during the three and six months ended September 30, 2017.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature Of Operations (Details Narrative)
6 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Date of Incorporation Nov. 18, 2005
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern (Details Narrative) - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 1,203,564 $ 1,180,182
Total Stockholders' Deficit $ 344,488 $ 321,106
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Accounting Policies [Abstract]        
Website Estimated Useful Life     3 years  
Amortization Expense, Website $ 1,344 $ 2,674
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Narrative) - USD ($)
Sep. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Related party advances $ 67,592 $ 67,113  
Chief Financial Officer [Member]      
Related party advances $ 479   $ 39,536
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details Narrative)
1 Months Ended
Oct. 31, 2018
Subsequent Events [Abstract]  
Description In October 2018, the Company received a $70,000 related party advance from an entity owned by Peptide’s CFO. The advance is due on demand and carries no interest. The advances are non-interest bearing.
EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 12 60 1 false 1 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://eternelleskincare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://eternelleskincare.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://eternelleskincare.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://eternelleskincare.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows Sheet http://eternelleskincare.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - Nature Of Operations Sheet http://eternelleskincare.com/role/NatureOfOperations Nature Of Operations Notes 6 false false R7.htm 00000008 - Disclosure - Going Concern Sheet http://eternelleskincare.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://eternelleskincare.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000010 - Disclosure - Related Party Transactions Sheet http://eternelleskincare.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 00000011 - Disclosure - Commitments And Contingencies Sheet http://eternelleskincare.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 10 false false R11.htm 00000012 - Disclosure - Subsequent Events Sheet http://eternelleskincare.com/role/SubsequentEvents Subsequent Events Notes 11 false false R12.htm 00000013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://eternelleskincare.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://eternelleskincare.com/role/SignificantAccountingPolicies 12 false false R13.htm 00000014 - Disclosure - Nature Of Operations (Details Narrative) Sheet http://eternelleskincare.com/role/NatureOfOperationsDetailsNarrative Nature Of Operations (Details Narrative) Details http://eternelleskincare.com/role/NatureOfOperations 13 false false R14.htm 00000015 - Disclosure - Going Concern (Details Narrative) Sheet http://eternelleskincare.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://eternelleskincare.com/role/GoingConcern 14 false false R15.htm 00000016 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://eternelleskincare.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://eternelleskincare.com/role/SignificantAccountingPoliciesPolicies 15 false false R16.htm 00000017 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://eternelleskincare.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://eternelleskincare.com/role/RelatedPartyTransactions 16 false false R17.htm 00000018 - Disclosure - Subsequent Events (Details Narrative) Sheet http://eternelleskincare.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://eternelleskincare.com/role/SubsequentEvents 17 false false All Reports Book All Reports pept-20180930.xml pept-20180930.xsd pept-20180930_cal.xml pept-20180930_def.xml pept-20180930_lab.xml pept-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 36 0001472375-18-000137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001472375-18-000137-xbrl.zip M4$L#!!0 ( (1P;4VZ+@=FFQ< &R1 1 <&5P="TR,#$X,#DS,"YX M;6SM75ESVSBV?K]5]S^@/%U=Z2K)UF)+MK-,*;*<44TBN[W,W'Z:@DA(0ILB M%(*4K?GU]YP#+J!$68MEQ^DD#XE- C@?#LX.$'GW]X>QQZ8BT%+Y[_>J^Y4] M)GQ'N=(?OM^[O2ZWKMO=[A[[^X?__9]W#_W DZ?X-X->OCY]T/+]WB@,)Z<' M!_?W]_OW]7T5# ]JE4KUX/^^?+YV1F+,R]+7(?<=L9?T\J1_5]2O>G)RYIK*P:<,TE4E35\RU MT\+9'ZKI ;R ]M7C3YH$8+(7<.("W24.IU6&MVGQL?J9%TB'2Y2'G MD[3#@.L^-8Y?%("!-X'RA"[L0V\*.OG*]Z-Q,2XW# ["V40<0*,RM!*!=-)^ MJSOE.P &?%R,CMX4H'-4Y(?!K'A)XI?8K9GOIH-PD0P\+*!PV;F\2=N*4 2^ M\(!3=])W>"#V'36F3I63>F4/](C!GW:%.1*#!A)_>F(9&$B)F$YZ;#_ MH-V]^#7.\/V>EN.)!R)\D QEU-)1?B@>0B;=]WOG@1H;F(> -%3FYY-R1C_M M)OQ0AK/T:?IYP D#V.6+N=S M2U\,B$:U6J[6OC/>&F,8?L@FD)*(W^R82=^C .:8E).DYV)2'0W+]\PDG,#S M,"DV:TW+K#6_2ZG*F;7F-F:M^0)F[?ODK26,S9?16*3QGSBD^D][),7@7/H0 M9DKN70P&TA'!%S'NB^";,3*3.S$<"XL#Z2L7P#Q,/.G(T&!EKH26)BF(IW9Z M)3R0,?<2Y'-V$W!?$!OKCS'[3>I!Z[T/2YQ%VO#LHI&RC/BB&_5V8\N9/ MP?C^!.,E+$;S>_?QS1?P\:"AS;]6ZM)\7:E+%DLU_UJQU.9\?M98*I7G:B63 M9_CYNS, <_),T]E4GFG>N^-SY$O#Y-OKLP5NC@7742 ^Q#6Q4VB3#):\RI/ MT9:,?SWB@=!+2<1,H$9;TP!\ETOHN'(*R[C(6^S;PPH9#Y7M'C?GP3S&HE$M MHF?"5V/PW2O(KN;+/-VB@9/W.2X4,=05\K1#,GTEAE*'$(F$/3X6+!:>*RRN M/58:PSI>]ZS#;CKM?_0N/E]\ZG:N2ZS;:^^_.U@V^"+Q-NA5P+VN[XJ'?XK9 MVM1MW5TZFDWN3#D1AC\WL\GZN1T% 3Z6VN'>'X('F\ZEG 0ZCXU6( "FY968 MJ""4_O ZY&&DUZ;Z!RK+JM$6J9Y+3P1M #14P?I"UU-^F3N.\%#=AU]\=;$1JE_@H67D47[-V_*WP M-=?@7[U>:7Q#?$7\>]#RU)?>^[TPB.RMG(3>621NE)4\2Z%C.["M$#6:1R>U MC O+"3P9RDIY:8"RU5\$RMH%F,?@'C9/GA_L)M6B1V7]Y*C>V 1N9N^ZOJ," M<#(<:S?HV2X&N4<;6/;*$5G>7""S:OAY_L'D92@^RZEPNSZ8W:'L>Z*EM0AO MM1A$WF?1M,;H??]+2!%XKMO:3N^QE:LUFH<9QL?I/1U= MT1[*AC9J*Y8L%'4>=2SUPY=ER4(I9$V6+$8Q)MS=+"+ZO584#UDC+7BE+$(! MY;X(,#04+ODBZ$5!R]KNXG)):%39KV">OP')W:%<]"0O@M+0:$7A2 7ROQ 4 MK\7#)5)/1S7'LY=!U=4Z>B*?K!!\!9FGH5F//SM$LS)'V2&# M'LM0-L>U.U85X,H"@VL8S/L8:>D+O;ZQ1 MLAQ>Y41:)=,8B& +Y3X&Z#T< M<,+]];-DJ]KPR'#K1S"Z)[8.Y*N51J.Y3C"#1'8":74"6*\?5K>%9%X\,;O) MI\BY(;>AMV'*NP:]K2=6!4L]3VDC$JOG8 MMSCRUK173K5>;P _-Z'=,_%Z.,[5:M6J7*%82VA6RE:QZ,C)@+IXSUI=\QL$6/I%11_7#H\/=RL; K!XE/+=RD\&"G/%8'&FEHXVY&-7$5F1[ VM:N;PMH=?\J01A\> M6R9WA\1783&7)O6X8UZ]63AAU9 M%0__-!0K&;,E"BL->=K^2RU?L)X?=TNZJPW(AG3_+>1P!*+1FHJ #T4OPFKQ MQ8!2,"L#^\BU=, $G4DO"N?RY+5JE^LG@MLA>KYY/5[U7#:OHT:E\;KG]7AA M];M>KT=*LB^]7KA=,1:?E=8(KPUPI1]!MXN),%L8^E($$/NY )NVRX/N4=@]Y4E*JO O7&6Y?5UX!Z4]G=$:]C6^H/G\&D67I= M0&9+)-N8M\/FM03D7<_AGD8P7% M'0!\HNP\/\"GR=6+,/ ),K5TW4.U:Z''")D['<9*/R^P_TXN]6X<1P??O2'+0@ZIE0WWP7'] M6] ;,SM_JG-[V/-KT?5[*A3)ODW^H.C.N;T)\5T#?R+'GP)]R6IU_:G0X2[D M>XW:PA, ;!P;5QNYC>7UJ<_C!N[B,4@-F?VL3%J6#@6L1/&GQP= M'SYF7=8!\GS3V71%CG)BOIO9G(E) #3,UP)BX@G\ 7M:Y[IW?^Q^':J[0KJ# M(_@@] ,9[JJ^,E)BD)7JUS[ ^:L7OITP'JU;>LU[JYO>JPBW-V<=FY:MUT+WK7V/Z@G_0\ MF-!/?ZO6X[]V"LE@ 8?S]EFH(I/+W)-#H/QG!'Y[,$N@E /<6P- Z0-/#,($ MX*68A&"6V8UP1K[RU!!4O41(P$SLLS?A2*1\K%7>QB=ITR? 6178#>+QK :_ ME=@]UTRFWQ()%WYA.# =^V=J /.:7V"T>3'7-&K"N._B2'$ GBOH?B_# M$31R)5B[,!X<#X\C*0T)GX$QB'Q?>(S#S&'(D(4P'4';NR..;X =B'H(:T07 M988EIA5^X\:@@X25P.%(K7V+R#Y;Q@,+QP0FR)T1P8BP@C45H4T99 ( X>VV M, S8+BUP.]B#Z8D)\6'(HR&P200#%8SQGECF\I"S 1@6BPZ(#K"/#SE>?,,4 M\"I@#D#BL+ HAPR\GE<.@0&$A-B&TFA!"CT*N,7V#>\ MA0&&'!-K0N'->%Y91V1_8 *Q&I5#54X6VBB140!D M#JPI#A(+:5Z(PWDI\(0YVH!L @W0,Q!0K83GF M4!@&>I^!Y*M5][MR5!9J :((W%" D 8'O^50 1[R M*Z&54;Z! #8W7*+)=V(&*Q6 /( V5AHS?FXV4SKY]362SAVH[6N1S80[(_28R Y<=8]$3 M*08(T8 [&'H%] ;[\F$@@#71!$+;V*V@5-/91+079BU!BZC Y('KP-_!A#$4QS+\CB9:XW,4 M1&]F()*]2F75GLH^N^*XF*582DE@C)8(](V.0'D)5#0< 26Z>R8"-9S -$98 M0HU[ 2]\X(1PEWLHGF6_I-!1_T]TH >N0,+X(!=9('4=YKX$8'C"?#<9YC& M2K 47N0FPH8$R8;P]!PD."!SPA)&=?!. C2EI/[DYH'I*@F:8P=K% I_)_R[6Q M?'NFHSG5(R#0QDF&M,=Q)(G1_4@ZH]C)ZBSL6&@A_0&8,11(;12/8@T*&!+_ MG(8^-DS"8%8@=5PZ@@%!7Q"2 *\'40UZ>@V9>&!,F$C:P4A(/ !L3%KL6N"D,7,@>(01Q",)("F1;?DVZHN+>2<"T?E MHS[=?P@A[)F*^F&K#P+V20&DMD+&^3<@X!\]Y=R]6+:Z7*GR*6P]E\)^NNCV M/K'V1:_=N>J]1.Z:3UE?TK" _1XD=VN8K(<*L^#:(![J"X%.38 8Q:Y14OT& ME0QMD!3#5+19=EGNR-E=S>[E_OLT^MUN5< M>DOJ0,(SGN!.0VIJ''-\T=CU?&B%FL;94,4V'04Q[U=')FG&XSTN.%&-"1.Y M LMD&G,5@Z_E?QGF5R.1V@"382"1A)C%L@WP;Z*.Q.990&&\+&* MFQ,VLJLN1";WJ;=!X3F ($6+8"H=8[DC#])B2F2!P@B32&P^@('- ED.>9SE MFQ ?@=.,W9K),T% HH#,>)(.S;!9+!8ZPOMRI.EK8*,DWX\$)9T+:<(J6."[ M!9YBBAFA1VP .02;*/!=P"8,(6/*5D3FBGZ8\$#$GU 9,)"UY%558I9F>*H6 M!TJF8"P)8? %#]@@0M>$M,="A(E! W$.D%Q@3%J.D>)A(G!EBE-("BM10R*, M/CW+#I1(#"Q,.8D T^.A%@_X5 5F%N#)32*+DS?N.D[X$99KJCUT#^1+1Y6O MT.FX*DYO*%!D:+M,O03[FR:!V6 V-0\!OSIH)KF5NSH>%G,PETA\06)#C;SS M,>W +&EK&V 2CC$FDDDVY NTTA1PCE3DN3G1,9IAR>^C!K: ^]:7@6M'4@LQ M6)9(M5+'?*GP\G"A7V_\=6C'7]?=3[WN>;?=ZMVP5KM]<=N[P7CL\N)SM]WM M//-FPNM3&!Q9X@]78(Y1G*Y T(8^&2!"(G\<7B0L2#+0P+ "+P'"?)X- ]R* MZW,=UQJI+*-'TN2M8 'H ?02$O!8F26DK:3,#A #+0XP#9L(4R-4)G UE9XR MC1#;]=@)FWK:J56K]%6^>$%@ C'D@;EE)J82!\?HOM]B-JTC0 X^5^"HE)H- M*.),"SA4G$!#:>[%2NH@&KP9:KW!E<2_8790_6WJ,$TJBDDQ%F3!#C]082_- M.M%XO8TK(QYFE(EME6A\N5;88F;"#JP;6-5P6A0TME@WQ%)@DE,*?RH#Y6.C M4A:QQSS(A5Z96P +E10S1Q*W7;#NF&!"8XTN'-)_X%(IR4&T6=DI&6"KKI:R MVY5Z$H44@1&.9-(BC8C6FS1$+8L-T75AS0B6#A.)Q7XLCC5P0P37")^+Q7)MFURB$%FEDC.?/F>GHN+UK3D% M@KN>9KOM(BCB8-$XA9+NY8T_!"4NCP1OZ6 M[OY3G9VD"\@,(^ERBE/>2&A#A24\!!1'-$%@O+FF]W$## !BTQ=GDXE6Q_BH MU/)&3K/FIJ9A+"@QA>>VU21T<\(DF$VV9@JSS[5RR,7;8(K_ZZLS""4\A0'0 MBZ>?#6A:*3RR=I2K]U]U/K=N.F?LLG5U\P>[N6KUKEOM%SBX]OJB@&4[MW0) MMV5)XFNX%W2T?7Z1,PGQ%A.XM,/FB?%M]9/24;V1N/DTZDU=UUH.$T="KY7W MD7$PK=B$S\@;J^3H<^(B3=DGB2WL/4UKOST&;4K +A;L?&@ZIH,1F$W0KK*O MS*8GQ RF5QR_F.(L*D$V3JC #" 3&LW2T4G-\ %^KE;K2_<)J-$7'C@C5J^: M1W,!09'J;J"$17?U2%-EP^^7J'8UA/0*=/Y5JG CI\+MBR]?NC=?.KV;:];J MG>'F'1:-.KT?L6)TDZ^H4V)J+J+S\+S.5'E3D$;&23HPS@TCP\!VCJ-YS)\.K$@:0N+3(8NE-O-A*]H MXUE\C:!W9XI#O"(I;>:D]/KVXW7G]UN04M;Y%\KJCR:979]=.*%"0V!;(_8W/'HHWW.K_(6794 MBF*[+DD+YBQ[8L?3!--7?CEI G$B1]=5'$DM$\S%X(DJ,U9EE^*MV6NKV/^L M0_^L0_^L0_^L0W_;.K0=[ZZPFP4?;,%RA;-+#[-;W\5O]$DI+P,1ZR!]O(:9 M,UY[EF4(;4P07I,9_EFH_EFH_K$+U;E/)9^BUHN?<=];E:]UF -L3/Z3:OP;?OU_4$L#!!0 ( (1P;4TVR6PY- 4 &\H 1 M<&5P="TR,#$X,#DS,"YX6S&]B*0R'L.+\^]XB/DZ.MC'*%[ M(B3E;.SXO;Z#" MX2-EB['R?NB?3T\G$05^__/7G2 9+$F,$"";'SE*IY-CS M'AX>>@^#'A<+[Z#?][W__KV<&CLG,SQ^C"C[V6;N#X=#S]06I@W+QYF("NJ! MIZMG6)(5,]12BSUE4F$6K-F':@6H&A]Z6>6:*6TU/\] MJ ![_[/;]]V!7YBGTEU@G*P@W9S?W*T 1!'!2 3]^$E9@ 7I!3PV MH/YPH!,R(C%AZH*+^(S,<1I!#'^E.*)S2D('*2P61%WAF,@$!V1;6LAH!+\1 M9HPKK"#_\Q)=EB24S3D4_#'267>L5;Z#OB#]\/UV\DPCVLH[XT&J_3YAX3E3 M5#U-@%+$IBD'T7#L6"UTX^"*:3XD<\JH\;&?_7SDH@)>?<0L1!D7JI"-O#I- MA3R5)+QF7\QS(H@$&@.ZA((#FX2PH) M?%/IV_5\P@! XPO*8#RF."K3M!CQNX'L4?I4CY*AUT&J-J#?\R;0JHW*![3; M8?S&83-WRF'V%/FZ-M=80^/UZ M"'(>9(A0E6FWU3_E<4R5&6QA,PNC@\Y,PLH/P69@CX%?CT&%"@$76B/;[3!, MTYDDOU+HU_E].24W2NV"'S3&G14>900[+K)M3.\P_&\W#?B#CM, [(WSIQW? M%C>W!&=$81K)*RQTP3W9M'5HV-DC]'&;K03ZD+.B%>V.QZ>Z"FV/C-7"'I-# MZ[IU'XQ.@UI[=+I![.%J[,:?'>3V =QN_=L>NZVM[6%K;,\WKX_W$7MNL;;A M*WO.RAZAQOZ]L9C[?P=&_]%GQK=DCLQ9\[$^DAP[DL9)I$^&3=E2D/G824BB MW.)\\ =TK?<81X6)IK:<-9N(UM7(&RXHL @:+(VS<"#AL&A0,,AYA?,%@:)* MP]?^]:7;@=6F]Q9=CO"L:YUD+6'?J:NG92MOVF'X M=+IV>/UK>Z?^GJT:J78W/X'WRB/X_+U^3#^"CG.A$&L<_-MN@F1W6"YY8*@L M$/WF%CA7%[G^@3OP>X\R+#WMXD0I0S1VGS0FX"Z0>W1&_K@/5V MRP893/NM0(]$2A8EK_2F>3/EY>X8KA?XL\6EG&U2I8J\RH Z5X8Z5_RC5SKS M,D=>[,5:\IEEOWC28G_:)DIMN.+%+4DZIXL4JGNF%* L2^!MD_? MC/IANQAT,I-*P*+:,1[;+Q&5MCA_&CM*I# $,1K!U*V'X>S=W*4[AA&;\O#. M3"QA*O*K2ME$DUD "^S#)HK$V@JD@.4D-)IJRV^"ITEA2,$DZ^+(R_2"Q]]0 M2P,$% @ A'!M394WA'H0!C=E>_W=]JM3+*^P\KCY,%*,VDN&IUSSHM L*5 M(R8F5ZUO@_;UX*;?;Q%MJ!A1+@5]N+AP M_&]#T1W)U5#Q<(R>$\+96L9O68Y\!(EFE]J'=R]=:OQP% Y#,B7LIW8HUK:W MVMWS=J][MM*C%D:/X-\F@DIR^ )C8M^_?>EO1P4#2@#GH'\PX5(%9Z[T'"OE MW$IW[H$PUV)T)PPSZ[X82^7YJ-$3W^Q4P?BJ-8.9P=&[[SH7O8X=^U497;.> M(<^:>3..D7%>"O@)OQ)F"H:YE%="EZIY8*@#0PU8 MOO3C^'$&RN>I,(CY6D>$>$/U]!.7RTH(=Y0.#/"!FKF"*O'+UCAX)FJ&$7A2 MH#$6_E"/X[Y !>9]8@)SC5'^'*OB]-S+W(&=^BQQ];B1.$]483E*DSUT?K*) M8&.J)R9/DS&50G*=EE \,^ MP9&B$Y<6LORHJ-'5+96V1WH%A MWDC/8\9/)%Q,D$,;&FP>2D2UA.JADV ^U/!SCB/>+HE;1[(Q M06(VCN]#^F8B!OH4*LYQ@,O?$(ZI'OJ[ MPKEN3RB=.99[![C1X1T_&]J=;K Y?!7<_GZM-0*XF2N[R0@'X'0(W!_V>R"7 M$'/J VS;>+N:X]O=SSE;4.ZO[^8&,WF-Y>5ORN>0[4A)]:2#D;2Y5BZ1:@3J MJM4-QZ'*C27+[DX]D'#TW-LD9IMA,H3Z8R6]O'@'L97[N!+E!5&TR!+89&I\ M]#7RN/&P*..:PD0&!>DT-2W4N"=#%^^QRH]PET;%A TY;* _0,ZD+](K1\UY M/=24<[IQ7-TS.F2<&6R0<&X/C'1_3"7'0&H[Q\TZFZUBS6:X5;C6I,G6707* MTI)(PFRW&Y=X55*M3'*=NACLR5".8"Y#[YVT=O*TK6;ZD^%8W]G+[3O)ZYB) MWT[1+!<\-(ZA?Y- _ZQ+Y)A$M.N;-@$(,;E;S4!HR.EH4D1KG.^?02 N3A6JG-9B,8@,MVHU"Q[EJ=24EBZI>,0.,J]=:_OL!9!?=2ETFZJ'!C&-KU M(,%1-I>[K+3KI06[RC*$),3JIB(5=18)*9)-FQR?I$(<8M-MN=$G=9\I$Q;Z M1QBCS%>ZRMGX5#%2=^-3AL$]HM+(]B?_]]Q8[_ VMW>PRF2C76O%L#B>E%PP M#,;']3=M-ZO;Z7:-#"W\CC:WG)2V4>.T1'QC9O(K8U2F 66Q(C6)&;?K<.-* MY2W,%+C,CP9><_"CB]V0)Y5A_\8>P>^R54Z[ <7Q93Q6"5+S>A)<&!10#;>P M>>^+X'F+!>@7 M+CVI-NI<>NC:7_:Q!QK(L5EB0Y&S!J4)-W0QRB$KN1AEA^!_DYK!P;(7I6:J MC4:5YP=I("PID1,'%8MRGI6&)G,.O86EN#AHC=S,Y!S_C.UD?K>G')AVN=0H MCQ\VBN0Q]@CT).<<]COW&?/FCZ0WOE7K3-2N_1Q8)EO3)&K[^.ZF'AJ-^?(N MZ8NO0K8Z)WB:7NK@: ST11)TQ 9Y-D*>K1S?C<(SI5$/NIVD!X$Z\?5)W,#Q MP99M;5>OR8[^SK#''=A;RPO2K MQ]7*1UUC7NXL\-G5N38NRQZ&C3FVL]KOE+]L?X(6T[[8?]7#._\!4$L#!!0 M ( (1P;4UM0)G8/ 4 ,LJ 5 <&5P="TR,#$X,#DS,%]D968N>&UL MU5I-;]LX$+TOL/^!4"_=@R(K;G:;(-XB==*%@;0)DA3H+: ERB9*D5Z23IQ_ MOZ0LR:+U[4I*U@=''_.&[\V,2'&<\T^;D( GQ 5F=&*Y1R,+(.HQ']/%Q/I^ M;U_<3V7Y^/GH>'S&^<(Y'(]?Y\?7ZWENB$-J8:G\>LA*4]E*$Y^')V.1WKL=TVP M\F6E2D+@<$549)Q?I?L9$AWC^R5"4M3Q*S3ND]"MND7E$DGL0=**72&R8ZKW M$DJD\R5N@IL5XE&>:H-8C>J1XA2*Y1?"GELQS($Z)O@-RC5';>)7CNB\$@56 M$;CE2*A81$/=!#.J #C\@JFJ-0S)+E;UY7F0NXY%_QM9KUZ.*6$>QA5%^G3< =$[Y#1&7(5].+?'G@D KH-:K: M.ES'-*9%QED#)CB79..FMRDG$:ZE<<&\]1[:/U4PMHOU!/% V M-*D73*6C3)W8QBETT#_O=##;9R'$+4GGT0,PCD:R0Q3.$6])UX3VSQ42THYA M!.B?%V7RHBVU!#-H3:( KHD\N"@3N,E97<84ZUGO6IT:O-%&(NHC/V&N'7;5 M8U"7M;/1]N,"&R2H["&D/MBZ (:/WB44MQ(,SL>*:+H?4L*/ 034M!H,\A_VR.^P@ 4@BQZ4=K[_8+ ^J62MP2!&]\ZZHB]A M4/Y3/W]8>(0)9:].MD!P,W"4#^U'&&+^VA<3>=5:LG[U>>P9I*Y!UG?O:@M[ M&8:4C_M2(@A(,?V7?:-VAL'Y=)]SQ@?8.0$[+[VKJ&UT9 6XHWT!,1Q$>& Z MZ)U[D]:'0=_=IY_Q )0+L.>C_QHJ:XT8M(]S99/"0()[W7*O+'MWW++LU=(; M'PVQZK9HFABJ/C19&,#[V!E(O0VAJ5%/Q5!S4CF=OI*,PUHKAJ[<\EU;>Z^B MM'7CQ1"96];+I^5"?;&Z1!]AGB&*Z%]Q&2_;3;6@M[ >'*T5T9 M!Q$IDBM1G\8>N?'/MN_BRX_I2X6*))JIPW0*(7".2#3V8VQ<9.N\ >H/<+[; MS5;0CNWV*>^JZ8(GY./=:L.6P':+?.:IQ4O5WQ6)1E/;;+30!PFS@+.P-IYQ M[%BE@FR %1$+,.XC/K'QFW%)GF[W&M!=I*??(>S)#D'Q+T\<:;L?(*. M1__C##VZ!>R[2E+2\3MPPNPABY'1TR5&0;K_OPG42Q/B7^/V>%E& M*T"/G6?6[-@WR-K>H\/:4'^;\^'E&CVPC$3U"CM=%4R )8)_M.S3I77(-=)9\%>+8@N5K6AR* T6NY&THKL*''_GK MN[LD)3[V14JWG&N )+(T,_QF]^/L>_;'GY[6(7K <4)H]/;H_,79$<*13P,2 MK=X>?9B?C.87T^D12E(O"KR01OCM442/?OK[G__T8TBBW][P_RR\!"-F)TK> M/"7D[=%]FF[>G)X^/CZ^>'SU@L:KTY=G9^>G__KE:N[?X[5W0B)NS\='I1:W M(M,[?_WZ]:GXM11M23XMXK!\QJO3$L[6,ON5:.0K2!+R)A'PKJCOI:(XC(]! M2@G^UTDI=L*_.CE_>?+J_,53$ARQTD/LG[P$8QKB6[Q$PLTWZ?.&%7%"UIN0 M@Q+?W<=X*0<3QO$IUS^-\,I+<< ?])H_Z/P[_J"OBJ^OO 4.CQ"7_' [5?KU MNF:K4#IU#7:&8T*#2=0/=5-[(/CSU(O3/1RHZCMWX8ZF7M@+?%73.>QKW*_$ M=WKN2YH%7MROI"N:GP5VVH;6/:J/M_%7I1X/F\WDG?/U5]&3R0IGRY1TR$[R+A*.3#_.COQ=B2,BACUSR/S^>[AXU'$DO[@E> M7I*(]7*(%]XLE\3'\2]XO<"QHC"T&BYI: &]RCN-.!BBF3$VF24TT%8%%3KH M8ZZU-\LVO!(X=\Y>OSH3S)E-9G>?QM3/UCA*1Q'K3*4D?9Y&2QJO1<=XM$C2 MF+TA#1\[Z+E@46LE09G5%>D35Z5JHCIHEP95;0/$;R2,GHEV'^QH@^G M 29YX&(?FO&*??4IAW&+5X1#C])K;XT;;JO%7'#*!))32"4S.&,,P)H$*3BQ MDT5<>$!>7#"VQEXX9;W$IY_QL]*[EIQ;9BA@UJG1$ +$#3DR!3D*822D$1,? MA!YE*+MC=B5^U7]V1089J)(#U=] 5+T$D+*]X#*#5O-VBF?,NMP:9QIRKBM> M"K/)@)H0*"K(D"DYD0NS;D2 N/@@]!@Q) %',XL[[E%J03,TBL:JP-UDJME"P\*6.C%HEQTV.A0.-AD>C 8A)%C!5R+HU&UO786 FW.3YN"8*@D@F=04;0^^]4X<-ZS"/?S6Z'Q(PF1+/E MH)NJR[TK79RI;F*QT1N)# MK@.#-1=>\9>?!"AC 9I1=>'#^S-OF?7I@UEZ\ZZCK=F]G%G=HN M31M%,*SK@K;%0J:$O"A /O^ =^HP"%E[H6Q>N@'#EC%<@2&,#%63&.*4#((8 MI%A'C*3XBCS@8!JE##-9A#@'>(U5)#$IN62-G0-5&NDUP/#*"F:3:+_B!>M. M'V2]_5#Q1OO:#!%AU*$%3-W7X,B#":0@34?OIE?3N^EDCD;78S2_N[GX^1\W M5^/)[?QK-)Y<3B^F=S"X.O)]FK$NV&09YQAN]HY8 @>UWT!-(IN"21&7B52&II,&0R0E2F1 V^723WN,8>06KPIT:#%)9 MLVEH&MGQ!S!QK!E3GWZZ@L88OL^.I&LQSQH%%S3B>[YQY#. JDE:G8;327$S M]-I4N%H<#*O,&%O3WCL-,?M=TX%!LQM5B[F-<2GYV=\7]1DN_C]K+TGL;D#QS\@,Y??G]\?O[R^+OOMC^3 M).&]*Q[.Z&['-_(2OGMESHI'$/R%%=(]>G6>?P6#HJ,@$-MK MO'#FD6 :77@;PCH#JJZH2MII]UX/N=:YEXN"H:\>7VN@N)5FW"7!"8F0GRO MX-(M3CT2X6#BQ1%[&1(V<,G6F1@,%V%940PVBFZSG=DZ4L]R9M("PSMKJ)*Y MBE(0!9":VG:WP;I_,72'S:ZC!H8[2FCR427@[IEI4:OG6ABL9<@^RX]@N&8) M5,Z\BK+H?@%F8J4;._/BFUCLA0Y$CW:&8W&RT-P!5FL.-)PPN:(88:C4P+#2 M'JMN'+(;?X#C8'Z4=;0= 9G+H:TQ$.=4T!5<:XI#Y)@"HXY;Q^U1+%"23<4X MVK802NE!R56'K"56+@J75#5\5H3*YSV DDF=4\%.95!:*?(IV,C#)9@YEX*4 M9?2P213VI]HT\ND:;X^H&18'E-(N"6: 7.660A0,K?3X6J=;A33:G2>$=G+P M9H-CCZ^ 39[XA@]L.D2HD7=)*"/L*J64PF!(94+8VE91RJ-2 0:;WN.( 0O9 M^'@4K$DD4C.GY $7*!7>&[5<,LO2A2J_#"I@6&:'L\FU0DM,6W@U/1B<:[T[ MMN_8P!'+*E(YY4Y:N1_)K@BU2S)9NU&EEE$)3.MFBU2^1;60A4&X2QIC MLHKR39!^] 5^98'ZGF$1"5X13[$ECP88EJ U.8_%)FBA!:XU8O=+N32LTDH<"?;>801ZVD_ MY+NV#,GP^MD:9K=Y#W?E>]$[& )#Z'W02].@Y>3FO97*I.7.Q!L89)_%=$E2 MS3BK*N"2EFU@5:[M?G5#H/I-]+H!5@N9;'0%9Z@]"OZ;)?G1Q6M6*8RX4Q:D M$YY:@E<2"7%MQ'A'.;>9CP\DP,&[YP\)3\[5)RY^[L>Z#:%N"K$>;3_O,P$% M9B>.ML\B;1^+4HKB\F$H*MY?_JU(<[D4@3YCST$D0MOI8N1M'P7C51_C#?." MB-$R^QQBD;,Z"D9K?LG8'^)[11W8J3K-Y]/!F5IF'PL],-3O +9UI49%-5]E MK^C X"-[9V/L)7B,\_]7WM+BF*!Y%YJU <=3=QT=:\S566J#X6EGR*T.\SW[ MBV^^K<5/D>!1D+>2XP5(O[GMJ3M0''*WH='6LL]UEJ#S%8O;-8$NP&7S:B%3UA MT0=>TAAP)UCA[#1ZP$FG$6P?0P H;>&H!;4U5L#$Z=[03;-Y6PL 9_.\9S%B MO:3QG"[31_4JN%32Z?R>&FIMHJ\M!F[&3PE1D9P>!?@!AW3#M6#PQOY=V?ME M@QH%]XM^X#;Y=,-M;M')-NA](2UZ<<':_BVZUA +ELX:L%IC17H+;H9NJE% MWUJ UZ*W1YO7-,7E4+.>_]MZP*HS,>R<@MDY_4R"6M\IBQ]PO* )UL7H'MB_ MI(SN]N_JWB\[U"B\7_3](GH4:MS*'L6F,($6SVBYC;O0.A7R2_#R2^R;;ZZB MR+J9&/XB0[USYOL,Y?I@.@\]0#L.YQ_0B)%97'IH>5]A\YK]F!7 M5+YT6IL;43?SE+5NNM#4#;KUC97':(%7).+9(_E^Q1S,_V>UOAJ@6B>1=DZE M&_ .E8IY/F.;ZG1X=#A>>5&Q,G]!HX2&)/"*E?X9*V$&7/Q9N7%\NY76F%GC M,+:='D\^9''4#C0?PC"8]NR0WK1.KU9L'Z.:=?%:5>W7+[/?/0+JBN#Z MJBH/QR3Q0YJP 9PI2':R (&9&M=L2"I1!\]7-69[ZL+@J^;ZSIV3A@#:T0:0 M"U?5[EE>P=HV (:W?5!WNJ85[A7P.*PKX7A=Q+&@6XTU,@\S/ M4S\D9,67#<:[.]W.ROG^\FPTPH;LG\'8D]W%CPKYFZQ!T M3DH^)]A_L:(/IP$F.979AR:#V5>?)@Q)^LQ34,4;FF]C&7LIOEG6OFH43!=% M%RSM[@CGI;W6X$SL#+654HE)\MUN-=F!=@2;[[>7]_1,6JZV>-N?KNZ 6;(3 MJ!1%@?DV[,\YZ+.ZM5QR_3>XZM!@E%_8!/A2\DO"Q@+XBCSPHTPI@TYX]AZ> M=>I#@I=9>$66JL,]=JI.[T#IX$SM\A,+O<%C=P^PJMP+DR0E:Q$2#\T*KP:FF$X0@2+Y4SBS8N5M3 M&) [$N :!E6DH?*H#;&=[WLK,5"KT/,N:K=M@*[,U=C4]PF7HNCC&"^]+$R1 M:%Z&:IGWN-H98#U(T*EK(A=&WW#Q;P8$-C]GE7DNUN#()3[A)0QD(_YG^&69"?5HG%[$*S'OA%*31*V?/# M_-U(,8,^5,4XRZX-IV)[@)95O$AD,JMDS/KF0W[-S+?2.\6&>O'ZI_*%4V,Z M=,VJ*65%9M12&M;+=?@,MW"JJ@?HCB^7+,7W0/7K-$=[>VX<=+Q;#;Q M).E]/'5HB;9YE467E)QX__H#)=G1)T7*$[ M*\PXH<''H_[)Z9&# Y=Z))A]//IR?SRXOQB-CAP>HL!#/@WPQZ. 'OW^S[__ M[3>?!-\^B+\FB&,'^ 3\PQ,G'X_F8;C\T.L]/CZ>/)Z=4#;KO3T][??^\^?U MO3O'"W1, L'/Q4<;*L&EBJY_?G[>BW^[&5H:^31A_N8[SGH;<;:"S>-751&)NC\6N;8@[\22S(J(_O M\-01_WZY&VV_%8>8!=CW,?]& A!5/* M%K'4H$G,=L[P]./1$B]#^/;^KZ?G9Z?BNW]2H0W72\"9D\72!\OT=A7W$_*% MC>_G&(>\2;[*P?L4: R_"L(Y#HF+?"WI*BD[%O4^1"$6>/';Z>T2LQBG1B/* MJ?8HX@7B\RN?/FI)6"+J6, ;%$8,Z]BOGJ)S3^0$+#!FF(,MXJ^ZG8X"(""+ M*Q* KQ'D/]NJV3U;L>M8J<\49H\+"G'"&M-1U=BN_9/, C*%&(6DY[HT@JP7 MS,;4)R[!S7ZJ0MRQP'?8!X0\2"_A^H&A@"-7R6N;Z#H6\X(N%B2,'0DF$\!0 MF :*!P6K*I!V[031A./O$7SCY4HEDNK&OZ1O=N*C>_;5JPD8)G[HYN7VQ M#J.LR7[CR_'#5YFL@PD/&?C$AI&/)MB/V7\5M&JDO3;""AMS,'*\-.38/9G1 M5<_#I"<4$#_$FAR?]M.%X4_PT==$B#L\(^*[@_ &+7"%Z#"T>F11TJQO#)CK M4.9A!I!M>"+FYCRBO)9-1_26\7KGV)T3?^M,4T87NK9,[48;%,F:%T1X>0PN M0!.&_!$$S],?>"T#H314$86^?3#4:&T$AXTB#\"WVOSY$8I6?VN3U:MT-&KL M,:P6*:C@#6%:E5N],%31_&%Q$3.EX1[B+_OQ@QJ>O7CU9$X;U-*#3I;G+V342[PTO*Q.I$;%M%7#H) MUU H O.S3<"HV, @.%?$Q^P"'&5&F;0P*@Q4A.(7^Z"HU-@@ N-H JOU*Y^B MJH7-5NS<,$7K_VJ?]2NT-9F:Z&)!@_N0NM_NYZ XOXW"^ DIA*@T04GI%-$Y MMP\=%7L8+6F3^2TI\:[@LYII1#)<>3UG$SJ-ZEL BB@ZE"')#%8%Q*H5=H/J M!E/:_0+Y_J>(DP!S:9%5&*@*@U5+;HG*!B&X7& V@XSYF=''< XY=8D":6U5 M0Z *B57+< 435$#S6Z^DX35\L/^]\>HNE=QF^%OGV-D^:H>?4Q(GI6GK7!O? MFB(^B?&)^/$,H67B8-@/^>:3HJ>E'W_="G4[W?8$C"DG#7OE*;D:=>O8V5V] M >=@WV9%BN-,[9MKV34?-S6:=)?)ND(C7<>J@E(:;FPW76[A*AAJ5+4##=%I M)1HNX)_+[Q%9(5\\<1R$%XBQ->3=?R$_JMKW2ND5R8WMPBL!0=NH9!.(.?44 M0\G@WGP+4"HUM,/XD)M)B*_)"GLCL%XP(Q,?)_+>8 D:373&-H]U,IR:\G8 ME8C5%!X&-X?UIQ:[#'Q-T(3X4)]@T<,7;_[,J0_&XB*1ANOFR5Z=@[&-R]V+ M,UTSV0%NVA3&QVB-(,:;)YN:\<;V--M:GRJI91-4PP@_T$P/'*C:")>,QMQ. M9S>8-=O##MPN%TN?KC%.1P 30>M76#:VYIJ1YALQT?AE$C%'H6,2!6QO2VS=B@DE<_,F(:MS5*@ M@^*_WWW3R.Z@'4J]GWF"W[0'6!JIBL\>5V>:B:].6SNP&'A>[%K@9(AXH^ " M+4GX?,"XHI*H(U!%9F_++_W*0:Z['0#=B1,Z ?8N$0L@!W,H=Z)%%->I0SPE M+I$D.A5:Y?US:V!3MX@=")85U)F:U!':V^I*&Z%ZC>U I*F4;;^+J([6WI93 MNU3F4FM8VQ)1?35&KC_B3-H?X;S)L?C'CWZ)%RC]P.2W+!;8B^NB,69Q/Z=2 M-5A/?+B=%1JVL2.-ECIQ!U$XIXS\]1S/4A#+1*9;+[I!K\X8EJ(VXCS20FQ# M8+KUHDNT\D:P%"EYYW^=:FWZ_O>VB]@E9FJ-_\9JE(9[L7+UR;M"??),Z]"I MDZ$VYXVC #3#6\&:BY%: H,AE5HRF%T^+7' L4+KIH3$<*W1@$@A?!I5MR/I M?<8!R.G#2F3@+4@07](@;B9)I:['J9'0=''1# #54\@FV$K*:024^4IBQTBJ M@ (TF&+&L'>=Z%\K9RQD2$/DQR/M #&QQS6M/)U3M$)VL+'+ 78#LJSOH4-Y M0P.:URYUUN8)3X'4=!^C'LS*MK CE5Y1ALDL2)Z2N]E;QCXC$@@G_82G,.8! M/=6#J,7$V$'Y5G"VL(\=P-[@4"6Q%H:9;D?5C+4J'0\]F3YK= 762;HA(D@F MS^NR,6;B.EP7BK4A\:,0>PU[F3NP--XSJ><1.QO/CN#]-^2<.8@V6('8,WP3 M+2:8W4YC23,;$05%ZAV@+3_CO99ZZ.]F-ENW<\J7B.=V<]Y+=W,$L9-06_&< M::N,UO.E"BHKVE@V1K= 6#ED*QRR=']*!68V?Z0/W+?!K<@ = M0]KA#)#N%%.<=&].F8?I3?(6<:YOHET+T0<[=OAJ%!\%*\QUZ\LVO$QO\G;G M*PHFLR,=0.**BZ,KRN[I-'R4;M=6#C9]WT";E62]TH>_I%3WR"Z"UX*-^+U& M[6MY>%.C<=I]V$EJE_(R?KZ^.R]1L)D=N;UJ+Z<,;G'O!@G]7ZAQT75 M,VQ:([:QDQVS@E47DK[(#1*[8=I\,:E>H"]C'P'Q6&AKN'?K#%_?6G%AQ7[< M02C7B4-#\FKV',-'C^+%XX2[OJ4PWCX3T+HW%IR5N>6S5"0/FRY M %&H3SR4/HC)OZ^]XD7M"D=BNF%OL@2L!;JBU*L8:[C3HU-\BY5??0Q8U(TE M&L;X[32O["@ K*HT+DZC'\IAG',541QEJ_X?\K9V;+.]'09C//RZ[05VA\D M- 8C+SB.5G?E#8% M^3V9!61*7%"@G.:JH_Z\&/49'LXS$V?+Y<<F=' .3-R)6Z]0<=LV41B]ZK!;N&1"%"-1B8C@, M57$L7?^H;2>;(E+E9N5<4/:+09GAX +)\_#RANTG^5O#E)--G9>&:X5M+I\ M#,=M*YS5[Q<_D#@6)3G^'@'?RU7M#E/_;:F.W9(Y*9W9!5I6!87S?[44AM>9 M6:$4EY4U)*;/\#5@4K$PE.IN5K!_IKD>=-YL?C)YF>LK6AK>8?"O M"(NS0V!XX1:Q>&NEFK21U/293.T5H;(Y[.A\&#-Q 4ZX'OLH>5GV]X@LQ>P[ M9GC)J!>YR7$M#E$E3N&#=CZ-!UQ0+GNQX.']0#7DE)SG2BUH9.S1 VE=RU#[>5$FFIG[F^?\.R'/I*>SJV=<*#.$\K*XORXYHB MK>2X-C5H%)7)7H-@ Q80K#B^"DT!C\Q8.S"I]J@Z!#+B9]_C:F&7TZ=U]C># M)R)!1X?' :&FHU9FJK4$S"%=P(I7#;3-6#O T7=)"7 ;U9ZK6),-2G."GQ>M MMU-84F'V)Q97<$NZD61$IDO >H\K-A@UJVY'L3Z,L+B2,WO31O)F"TG-(Z,Q MC5#]-%N\*+11\8Z?D5K3*J96S)<./I5:QRRKX5]I.YEX6*.N0C+ZL)O(LAK; MD20+$F;./"HCDZ,QGB1W JA"?:T]C/0WXJ\)XA@^^3]02P$"% ,4 " "$ M<&U-NBX'9IL7 !LD0 $0 @ $ <&5P="TR,#$X,#DS M,"YX;6Q02P$"% ,4 " "$<&U--LEL.30% !O* $0 M@ '*%P <&5P="TR,#$X,#DS,"YX$>AP& M 4.0 %0 @ $M'0 <&5P="TR,#$X,#DS,%]C86PN>&UL M4$L! A0#% @ A'!M36U F=@\!0 RRH !4 ( !?", M '!E<'0M,C Q.# Y,S!?9&5F+GAM;%!+ 0(4 Q0 ( (1P;4VC\>EEVA( M ('X 5 " >LH !P97!T+3(P,3@P.3,P7VQA8BYX;6Q0 M2P$"% ,4 " "$<&U-QD9')O8- ":PP %0 @ 'X.P K<&5P="TR,#$X,#DS,%]P&UL4$L%!@ & 8 B@$ "%* $! end